---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-064429"
form_type: "8-K"
ticker: "SPRB"
cik: "0001683553"
company_name: "SPRUCE BIOSCIENCES, INC."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T12:46:38.341192+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Spruce Biosciences Q1 net loss $14.0M; cash runway to end 2025; TA-ERT BLA in 1H 2026

## Summary
- Q1 2025 net loss $14.0M vs $11.6M YoY; R&D includes $5.7M for SPR202 acquisition.
- Cash and equivalents $25.6M, expected to fund current operating plan through end of 2025.
- TA-ERT for MPS IIIB: BLA submission to FDA expected in 1H 2026; FDA confirmed HS-NRE as surrogate endpoint for accelerated approval.
- Tildacerfont Phase 2 TAMARIND MDD study topline results expected 1H 2026; HMNC funding and conducting study.
- Stock now trades on OTC Pink under SPRB after NYSE delisting.

## SEC filing metadata
- accession: 0000950170-25-064429
- form_type: 8-K
- ticker: SPRB
- cik: 0001683553
- company_name: SPRUCE BIOSCIENCES, INC.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1683553/000095017025064429/0000950170-25-064429-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1683553/000095017025064429/sprb-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-064429
- JSON: https://secwatch.observer/filing/0000950170-25-064429.json
- Plain text: https://secwatch.observer/filing/0000950170-25-064429.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.